| Literature DB >> 23006752 |
Pietro Lo Giudice1, Silvia Campo, Rita De Santis, Giovanni Salvatori.
Abstract
This study evaluated the pharmacological activity of PTX3, administered in combination with voriconazole, in a rat model of pulmonary aspergillosis. The data indicated additive therapeutic activities of these compounds, as demonstrated by the amelioration of respiratory function changes, reduction of lung fungal burden, and increased survival. Overall, we provide clear evidence that the combination of PTX3 with a suboptimal dose of voriconazole might represent a therapeutic option under those clinical conditions where the use of voriconazole alone is not warranted for efficacy and tolerability reasons.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23006752 PMCID: PMC3497210 DOI: 10.1128/AAC.01000-12
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN: 0066-4804 Impact factor: 5.191